Literature DB >> 28624923

A comparison of enhancement patterns on dynamic enhanced CT and survival between patients with pancreatic neuroendocrine tumors with and without intratumoral fibrosis.

Cherry Kim1,2, Jae Ho Byun3, Seung-Mo Hong4, Soyeon An4, Jin Hee Kim1, Seung Soo Lee1, Hyoung Jung Kim1.   

Abstract

PURPOSE: To compare CT findings and survival between patients with pancreatic neuroendocrine tumors (pNETs) with and without fibrosis.
METHODS: Forty-five pNET patients with intratumoral fibrosis (group A) were matched for age, gender, and tumor size and grade with 45 pNET patients without (group B), and CT images were retrospectively reviewed. Hounsfield units (HUs) of tumors in unenhanced, arterial and portal phases, HU ratio (tumor to normal parenchyma) in each phase, enhancement patterns, visible enhancement pattern changes, and survival were compared.
RESULTS: Group A showed progressive enhancement patterns, while group B showed early enhancement and wash-out patterns (p < 0.05). HUs of tumors and HU ratio in the unenhanced phase were significantly higher in group A than group B (p ≤ 0.024), whereas those in the arterial phase were significantly lower in group A than group B (p ≤ 0.003). Peripheral to full or peripheral to peripheral enhancement change was more frequent in group A, while full to full enhancement change was more frequent in group B (p < 0.05). Group A showed significantly lower overall survival than group B (p = 0.029).
CONCLUSIONS: pNETs with fibrosis showed a progressive enhancement pattern and worse overall survival than pNETs without, which showed an early enhancement and wash-out pattern.

Entities:  

Keywords:  Dynamic enhanced CT; Enhancement pattern; Fibrosis; Neuroendocrine tumor; Pancreas

Mesh:

Substances:

Year:  2017        PMID: 28624923     DOI: 10.1007/s00261-017-1212-6

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  4 in total

1.  Qualitative imaging features of pancreatic neuroendocrine neoplasms predict histopathologic characteristics including tumor grade and patient outcome.

Authors:  Motoyo Yano; Anup S Shetty; Greg A Williams; Samantha Lancia; Nikolaos A Trikalinos; Chet W Hammill; William G Hawkins; Amber Salter; Deyali Chatterjee
Journal:  Abdom Radiol (NY)       Date:  2022-02-15

Review 2.  What Is New in the 2017 World Health Organization Classification and 8th American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Neoplasms?

Authors:  Jooae Choe; Kyung Won Kim; Hyoung Jung Kim; Dong Wook Kim; Kyu Pyo Kim; Seung-Mo Hong; Jin-Sook Ryu; Sree Harsha Tirumani; Katherine Krajewski; Nikhil Ramaiya
Journal:  Korean J Radiol       Date:  2018-12-27       Impact factor: 3.500

3.  CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors.

Authors:  Damiano Caruso; Michela Polici; Maria Rinzivillo; Marta Zerunian; Ilaria Nacci; Matteo Marasco; Ludovica Magi; Mariarita Tarallo; Simona Gargiulo; Elsa Iannicelli; Bruno Annibale; Andrea Laghi; Francesco Panzuto
Journal:  Radiol Med       Date:  2022-06-18       Impact factor: 6.313

4.  Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal-venous enhancement phase.

Authors:  Christian Philipp Reinert; Karolin Baumgartner; Tobias Hepp; Michael Bitzer; Marius Horger
Journal:  Abdom Radiol (NY)       Date:  2020-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.